4.5 Review

Are extracellular microRNAs involved in type 2 diabetes and related pathologies?

Journal

CLINICAL BIOCHEMISTRY
Volume 46, Issue 10-11, Pages 937-945

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2013.02.018

Keywords

MicroRNA; Diabetes; Exosomes; Circulating microRNA; Microparticles

Funding

  1. Fondation pour la Recherche Medicale (FRM)
  2. Association Francaise de recherche sur les Myopathies (AFM)
  3. Association Francaise de Diabetologie (SFD) and INRA specific grant (ANSSD)

Ask authors/readers for more resources

MicroRNAs (miRNAs) are a class of evolutionary conserved non-coding RNAs of 19-22 nucleotides that function as negative regulators of gene expression. Originally discovered in C elegans, miRNAs regulate fundamental cellular processes in diverse organisms, including the control of metabolic pathways involved in fat metabolism, adipocyte differentiation, energy homeostasis, glucose-stimulated insulin secretion and inflammation. Several miRNAs have been identified as having a physiological role in tissues in which type 2 diabetes (T2DM) complications occur (liver, pancreas, adipose tissue and skeletal muscle). In addition, previous studies in animal models or in human tissues have demonstrated altered expression of microRNAs in insulin-sensitive tissues of T2DM patients suggesting a potential role for these small RNA molecules in the complications associated with the diabetic condition. However all these data assume that miRNAs reside and elicit their regulatory action within the producing cells. However, studies in the last 5 years have demonstrated that miRNAs are not only found intracellularly, but are also detectable outside cells, including in various body fluids. This phenomenon raises questions about the biological functions of such extracellular miRNAs. The aim of the present review is to summarize the current knowledge of the impact of extracellular miRNAs on the development of obesity-associated T2DM, and its related complications including endothelial and vascular smooth muscle cell dysfunction. It also considers the possible use of blood miRNAs as biomarkers for the detection of T2DM, classification of the disease and detection of associated pathologies. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available